BIVICTRIX THERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10 GBX | 0.00% |
|
-13.04% | -4.76% |
| Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
| Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 19.5 | 11.24 | 8.253 | 8.253 | - |
| Enterprise Value (EV) 1 | 19.5 | 8.06 | 19.01 | 37.15 | 35.45 |
| P/E ratio | -4.9 x | -4.5 x | -0.56 x | -0.39 x | 2.28 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 0.83 x |
| EV / Revenue | - | - | - | - | 3.55 x |
| EV / EBITDA | - | -2.85 x | -1.61 x | -2.06 x | 29.8 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 66,115 | 66,115 | 82,526 | 82,526 | - |
| Reference price 2 | 0.2950 | 0.1700 | 0.1000 | 0.1000 | 0.1000 |
| Announcement Date | 3/7/22 | 3/30/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 10 |
| EBITDA 1 | - | -2.824 | -11.8 | -18.04 | 1.188 |
| EBIT 1 | - | -2.975 | -12.21 | -18.48 | 0.718 |
| Operating Margin | - | - | - | - | 7.18% |
| Earnings before Tax (EBT) 1 | - | -2.971 | -12.2 | -18.6 | 0.431 |
| Net income 1 | -2.34 | -2.497 | -11.74 | -17.04 | 2.905 |
| Net margin | - | - | - | - | 29.05% |
| EPS 2 | -0.0602 | -0.0378 | -0.1780 | -0.2580 | 0.0439 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 3/7/22 | 3/30/23 | - | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 10.8 | 28.9 | 27.2 |
| Net Cash position 1 | - | 3.18 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.9119 x | -1.602 x | 22.89 x |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share 2 | - | -0.0400 | -0.1800 | -0.2700 | - |
| Capex 1 | - | - | 0.22 | 0.24 | 0.25 |
| Capex / Sales | - | - | - | - | 2.5% |
| Announcement Date | 3/7/22 | 3/30/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1
GBP
Average target price
0.66
GBP
Spread / Average Target
+560.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.76% | 10.48M | |
| +41.79% | 54.04B | |
| -0.56% | 41.92B | |
| +49.17% | 41.96B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| -21.51% | 19B | |
| +6.92% | 13B | |
| +24.91% | 12.19B | |
| +29.60% | 12.28B |
- Stock Market
- Equities
- BVX Stock
- Financials BiVictriX Therapeutics Plc